Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Mergers & Acquisitions
Genentech buys liver disease–focused Jecure
by Lisa M. Jarvis
December 1, 2018
| A version of this story appeared in
Volume 96, Issue 48
Genentech has agreed to buy Jecure Therapeutics for an undisclosed sum. San Diego–based Jecure came out of stealth last year with $20 million from Versant Ventures to develop small molecules for nonalcoholic steatohepatitis (NASH), a serious liver disease. The deal gives Genentech a portfolio of early-stage compounds that block NLRP3, an immunomodulatory protein that helps trigger cellular inflammatory responses. In addition to NASH, NLRP3 inhibitors could be relevant in gout, inflammatory bowel disease, and cardiovascular diseases.
Chemical & Engineering News
ISSN 0009-2347
Copyright © 2024 American Chemical Society
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter